Inventor · disambiguated record
Fabio Tucci
Also filed as: TUCCI FABIO · TUCCI FABIO C
20 granted patents·17 pending applications·217 citations·filing 2000–2025
94Inventor score
Files withNEUROCRINE BIOSCIENCES INC18EPIGEN BIOSCIENCES INC7CURTANA PHARMACEUTICALS INC5BRUIN BIOSCIENCES INC2DTX PHARMA INC2
Top patents by PatentIndex Score
37 records- 0195US7419983B2Gonadotropin-releasing hormone receptor antagonists and methods related theretoNEUROCRINE BIOSCIENCES INC·Filed 2007·Granted Sep 2, 2008·38 cites·40 claims
- 0294US7176211B2Gonadotropin-releasing hormone receptor antagonists and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2005·Granted Feb 13, 2007·32 cites·20 claims
- 0393US7056927B2Gonadotropin-releasing hormone receptor antagonists and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2004·Granted Jun 6, 2006·49 cites·45 claims
- 0489US6608197B2Gonadotropin-releasing hormone receptor antagonists and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2001·Granted Aug 19, 2003·31 cites·37 claims
- 0588US7462625B2Gonadotropin-releasing hormone receptor antagonists and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2006·Granted Dec 9, 2008·9 cites·20 claims
- 0686US6346534B1Gonadotropin-releasing hormone receptor antagonists and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2000·Granted Feb 12, 2002·24 cites·38 claims
- 0783US10570103B2Heterocyclic compounds useful in the treatment of diseaseEPIGEN BIOSCIENCES INC·Filed 2018·Granted Feb 25, 2020·3 cites·24 claims
- 0883US6872728B2Gonadotropin-releasing hormone receptor antagonists and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2003·Granted Mar 29, 2005·16 cites·86 claims
- 0982US10227333B2Inhibition of OLIG2 activityCURTANA PHARMACEUTICALS INC·Filed 2016·Granted Mar 12, 2019·3 cites·15 claims
- 1080US7179815B2Gonadotropin-releasing hormone receptor antagonists and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2004·Granted Feb 20, 2007·11 cites·18 claims
- 1175US12234224B2Pyrimidine and pyridine amine compounds and usage thereof in disease treatmentEPIGEN BIOSCIENCES INC·Filed 2023·Granted Feb 25, 2025·0 cites·18 claims
- 1275US2023271926A1Inhibition of olig2 activityCURTANA PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1370US12357570B2Chemoembolization agentsBRUIN BIOSCIENCES INC·Filed 2023·Granted Jul 15, 2025·0 cites·18 claims
- 1468US11691951B2Inhibition of Olig2 activityCURTANA PHARMACEUTICALS INC·Filed 2021·Granted Jul 4, 2023·0 cites·8 claims
- 1567US11427552B2Heterocyclic compounds useful in the treatment of diseaseEPIGEN BIOSCIENCES INC·Filed 2020·Granted Aug 30, 2022·0 cites·20 claims
- 1665US2021114991A1Inhibition of olig2 activityCURTANA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1763US11866421B2Pyrimidine and pyridine amine compounds and usage thereof in disease treatmentEPIGEN BIOSCIENCES INC·Filed 2021·Granted Jan 9, 2024·0 cites·21 claims
- 1863US2023286928A1Heterocyclic compounds useful in the treatment of diseaseEPIGEN BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 1962US10526298B2Heterocyclic compounds useful in the treatment of diseaseEPIGEN BIOSCIENCES INC·Filed 2018·Granted Jan 7, 2020·0 cites·47 claims
- 2062US6677340B2Gonadotropin-releasing hormone receptor antagonists and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2002·Granted Jan 13, 2004·1 cites·11 claims
- 2161US10000459B2Heterocyclic compounds useful in the treatment of diseaseEPIGEN BIOSCIENCES INC·Filed 2014·Granted Jun 19, 2018·0 cites·19 claims
- 2261US2025376487A1Lipid-modified nucleic acid compounds and methodsNOVARTIS AG·Filed 2025·Application pending·0 cites
- 2358US11712418B2Chemoembolization agentsBRUIN BIOSCIENCES INC·Filed 2018·Granted Aug 1, 2023·0 cites·12 claims
- 2452US2024279267A1Lipid-modified nucleic acid compounds and methodsNOVARTIS AG·Filed 2019·Application pending·0 cites
- 2550US2004162290A1Gonadotropin-releasing hormone receptor antagonists and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2003·Application pending·0 cites
- 2649US2006019996A1Gonadotropin-releasing hormone receptor antagonists and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2005·Application pending·0 cites
- 2748US6939883B2Gonadotropin-releasing hormone receptor antagonists and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2002·Granted Sep 6, 2005·0 cites·5 claims
- 2848US2018244631A1Inhibition of olig2 activityCURTANA PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2946US2005119252A1Ligands of melanocortin receptors and compositions and methods related theretoNEUROCRINE BIOSCIENCES INC·Filed 2004·Application pending·0 cites
- 3045US2004142942A1Gonadotropin-releasing hormone receptor antagonists and methods relating theretoFiled 2003·Application pending·0 cites
- 3145US2023108783A1Compounds and methods for the treatment of duchenne muscular dystrophyDTX PHARMA INC·Filed 2020·Application pending·0 cites
- 3245US2023158150A1Compound comprising a nucleic acid and a half-life extension motifDTX PHARMA INC·Filed 2020·Application pending·0 cites
- 3343US2002077327A1Gonadotropin-releasing hormone receptor antagonists and methods relating theretoNEUROCRINE BIOSCIENCES INC·Filed 2001·Application pending·0 cites
- 3442US2003158209A1Ligands of melanocortin receptors and compositions and methods related theretoNEUROCRINE BIOSCIENCES INC·Filed 2002·Application pending·0 cites
- 3541US2005192286A1Ligands of melanocortin receptors and compositions and methods related theretoNEUROCRINE BIOSCIENCES INC·Filed 2004·Application pending·0 cites
- 3640US2004192676A1Ligands of melanocortin receptors and compositions and methods related theretoNEUROCRINE BIOSCIENCES INC·Filed 2003·Application pending·0 cites
- 3740US2004053933A1Ligands of melanocortin receptors and compositions and methods related theretoNEUROCRINE BIOSCIENCES INC·Filed 2003·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Fabio Tucci files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →